Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Filamon LTD
Psyence Australia Pty Ltd
ViroMissile, Inc.
Dana-Farber Cancer Institute
University of Florida
Tizona Therapeutics, Inc
Essen Biotech
Essen Biotech
Sapience Therapeutics
Daiichi Sankyo
Second Life Therapeutics
Innate Pharma
Ohio State University Comprehensive Cancer Center
Mayo Clinic
NeoTX Therapeutics Ltd.
DualityBio Inc.
M.D. Anderson Cancer Center
Hangzhou DAC Biotechnology Co., Ltd.
Washington University School of Medicine
Fudan University
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
Columbia University
Theratechnologies
Seagen Inc.
Cedars-Sinai Medical Center
Algemeen Ziekenhuis Maria Middelares
University of Toronto
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
RECORDATI GROUP
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
Pfizer
Cedars-Sinai Medical Center
Exelixis
NGM Biopharmaceuticals, Inc
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Klus Pharma Inc.
Kineta Inc.
Eastern Cooperative Oncology Group
Xencor, Inc.
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
Xencor, Inc.
Ludwig Institute for Cancer Research
Imperial College London
Peter MacCallum Cancer Centre, Australia